Probióticos profilácticos para prematuros de peso extremadamente bajo al nacer (PROPEL)
Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis, and severe infections. Feeding intolerance is also a common problem resulting in prolonged need for intravenous lines and poor nutrition.
The aim of the study is to evaluate whether supplementation with the probiotic bacterium Lactobacillus reuteri DSM 17938 daily to premature infants with extremely low birth weight increases feeding tolerance to breast milk and thereby improves nutrition, increases growth and reduces serious complications and mortality in this population. Follow ups will be conducted at 2. 5,5- and 14 years of age for evaluating neurodevelopment, lung function and physical fitness. Beyond this, possible mechanisms underlying these effects will be analyzed in stool, breast milk and blood samples.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
RATIONALE Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis (NEC), and severe infections. Feeding intolerance is also a common problem resulting in prolonged need for intravenous lines and poor nutrition. There is scientific evidence that dietary supplements with probiotics may have an effect on these manifestations.
Lactobacillus reuteri is a well studied probiotic bacterium that has been tested in several clinical studies in premature infants and older children, and the results of these studies and animal studies suggest that this bacterium may also have an effect on growth and mortality in extremely premature infants. Lactobacillus reuteri reduces colonization with pathogenic microbes, stimulates gastric and intestinal motility and shortens hospital stay in moderately premature infants. In animal models, L. reuteri also induces anti-inflammatory immune responses, reduces the symptoms of inflammatory bowel disease and the incidence of NEC. Administration of L. reuteri also improves the intestinal barrier both in human studies in children and in animal studies. Dietary supplements of L. reuteri to extremely premature infants may therefore improve feeding tolerance and nutrition and reduce the incidence of severe complications during the neonatal period and later in childhood in this population.
HYPOTHESIS Primary: premature infants with extremely low birth weight receiving daily supplements of Lactobacillus reuteri DSM 17938 will reach full enteral feeding faster compared with children receiving placebo.
STUDY DESIGN This study will be conducted as a prospective multi-center double blind placebo-controlled study in neonatal intensive care units in Sweden. In total 134 neonates with extremely low birth weight (<1000g) and gestational age <28+0 weeks will be randomized to receive either dietary supplements of Lactobacillus reuteri or placebo. Study product will be identical to the active and placebo group besides the addition of Lactobacillus reuteri (1.25 x 100 million bacteria=0.2 ml oil drops per day) in the active group. The supplementation will commence within 1-3 days after birth and will be given daily until gestational week 36+0. The infants will be followed until gestational week 36+0 and data on feeding tolerance, nutrition, growth, infections, NEC, bronchopulmonary dysplasia, death, and potential confounders will be entered in an individual study protocol. Stool, breast milk, and blood samples will be collected for analyses of possible underlying mechanisms.
A 2- and 5.5- year follow up including examination by pediatrician, growth parameters, questionnaire and psychology testing will be performed.
A 14-year follow up will be performed with lung function tests and test for physical fitness.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Linköping, Suecia, 581 85
- Crown Princess Victoria Chilkdren´s Hopstial, University Hospital
-
Norrköping, Suecia, 60379
- Vrinnevi Hospital in Norrköping
-
Stockholm, Suecia, SE-171 76
- Karolinska
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Birth weight < 1000 g
- Gestational age: v23+0-V27 +6.
- Age < 72 hours at inclusion.
- Signed informed consent by parents.
Exclusion Criteria:
- Fatal or complex congenital malformation at inclusion time.
- Chromosomal defect at inclusion time.
- No realistic hope of survival at inclusion time.
- Gastrointestinal malformation at inclusion time.
- Participation in another study which aims to influence nutrition, growth, feeding tolerance or necrotizing enterocolitis.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Lactobacillus reuteri
Lactobacillus reuteri DSM 17938, 125 million bacteria/day |
Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day |
|
Comparador de placebos: Placebo
The same oil drops as the active study product but without Lactobacillus reuteri |
Oil drops without Lactobacillus reuteri |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Establish Full Enteral Feeds
Periodo de tiempo: Birth to gestational week 36+0
|
The age of the infants in days when the infant receive 150 ml/kg/day via enteral feeding for the first time. |
Birth to gestational week 36+0
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de taburetes
Periodo de tiempo: Grabado durante las primeras cuatro semanas.
|
Grabado durante las primeras cuatro semanas.
|
|
|
Mortalidad
Periodo de tiempo: Nacimiento a gw 36+0
|
Nacimiento a gw 36+0
|
|
|
Days With Halted Feeding Due to Food Intolerance
Periodo de tiempo: Birth to gestational week 36
|
Episode with food intolerance. Retention volume> food volume given the last 2 hours (retention checked routinely every 4 hours) and/or clinical signs consistent with necrotizing enterocolitis (reduced general condition and inflated abdomen). The number of such events will also be indicated. |
Birth to gestational week 36
|
|
Time Until Birth Weight is Regained. Specifies the Number of Full Days the Child Has Lived.
Periodo de tiempo: Birth to gw 36+0
|
Specifies the number of full days the child has lived. |
Birth to gw 36+0
|
|
Weight Gain (SD)
Periodo de tiempo: At 14th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 14th day of life
|
|
Necrotizing Enterocolitis
Periodo de tiempo: Birth to gw 36+0
|
Bell´s criteria II-III |
Birth to gw 36+0
|
|
Sepsis
Periodo de tiempo: Birth to gw 36+0
|
Blood culture positive sepsis |
Birth to gw 36+0
|
|
Bronchopulmonary Dysplasia
Periodo de tiempo: Gw 36+0
|
Need of oxygen or CPAP/ventilator at gw 36+0 |
Gw 36+0
|
|
Weight Gain (SD)
Periodo de tiempo: At 28th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 28th day of life
|
|
Weight Gain (SD)
Periodo de tiempo: At gestational week 36+0
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At gestational week 36+0
|
|
Length Gain (SD)
Periodo de tiempo: At 14th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 14th day of life
|
|
Length Gain (SD)
Periodo de tiempo: At 28th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 28th day of life
|
|
Length Gain (SD)
Periodo de tiempo: At gestational week 36+0
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At gestational week 36+0
|
|
Head Circumference Growth (SD)
Periodo de tiempo: At 14th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 14th day of life
|
|
Head Circumference Growth (SD)
Periodo de tiempo: At 28th day of life
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At 28th day of life
|
|
Head Circumference Growth (SD)
Periodo de tiempo: At gestational week 36+0
|
In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict. |
At gestational week 36+0
|
|
Neurological Development 2y
Periodo de tiempo: At 2 years corrected age
|
Bayleys´s test by psychologist |
At 2 years corrected age
|
|
Neurological Development Impairment
Periodo de tiempo: At 2 years corrected age
|
A composite of several outcomes: impaired cognition at the Bayleys´test, cerebral palsy, blindness and deafness, divided into normal, mild, moderate and severe. Mild -1SD to -2SD, Moderate <-2D to 3 SD and Severe <3SD |
At 2 years corrected age
|
|
Neurodevelopmental Impairment at 5y
Periodo de tiempo: 5.5 years of age +/-6 months
|
Wechsler Preschool and Primary Scale of Intelligence (WPPSI) by psychologist; Cerebral Palsy by physician and physiotherapist: vision by ophtalmologist, deafness by audiologist. The diagnoses will be measured both separately and collectively as a composite, neurodevelopment impairment (NDI). A total WPPSI will be calculatated as continuous data, whereas the other variables will be dichotomized |
5.5 years of age +/-6 months
|
|
Lung Function at 14 y
Periodo de tiempo: 14 years of age +/-6 months
|
Lung function assessed with dynamic and static spirometry, Impulse oscillomtry (IOS), and Diffusing capacity of the lungs for carbon monoxide (DLCO). To distinguish between allergic asthma and non-allergic lung impairment, allergen specific IgE will be measured together with an allergy questionnaire. |
14 years of age +/-6 months
|
|
Physical Fitness at 14y
Periodo de tiempo: 14 years of age +/-6 months
|
Physical fitness will assessed with three measures: long standing jump, hand grip strength, and 20 m beep test |
14 years of age +/-6 months
|
|
Anthrometry at 14y
Periodo de tiempo: 14 years f age +/-6 months
|
Weight, length, head circumference, and body composition with an impedance scale |
14 years f age +/-6 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Thomas Abrahamsson, MD, PhD, Linköping University Hospital; County Council of Östergötland
Publicaciones y enlaces útiles
Publicaciones Generales
- Spreckels JE, Wejryd E, Marchini G, Jonsson B, de Vries DH, Jenmalm MC, Landberg E, Sverremark-Ekstrom E, Marti M, Abrahamsson T. Lactobacillus reuteri Colonisation of Extremely Preterm Infants in a Randomised Placebo-Controlled Trial. Microorganisms. 2021 Apr 24;9(5):915. doi: 10.3390/microorganisms9050915.
- Marti M, Spreckels JE, Ranasinghe PD, Wejryd E, Marchini G, Sverremark-Ekstrom E, Jenmalm MC, Abrahamsson T. Effects of Lactobacillus reuteri supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial. Cell Rep Med. 2021 Feb 22;2(3):100206. doi: 10.1016/j.xcrm.2021.100206. eCollection 2021 Mar 16.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades intestinales
- Enfermedades del sistema inmunológico
- Infecciones
- Enfermedades de las vías respiratorias
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Enfermedades pulmonares
- Enfermedades bronquiales
- Enfermedades Pulmonares Obstructivas
- Hipersensibilidad Respiratoria
- Hipersensibilidad, Inmediata
- Hipersensibilidad
- Gastroenteritis
- Enterocolitis
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Asma
- Peso corporal
- Enfermedad
- Septicemia
- Enterocolitis Necrotizante
- Fracaso para prosperar
Otros números de identificación del estudio
Otros números de identificación del estudio
- Dnr 2012/28-31
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .